The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 2, 2015, Pages 177-185

  Kaur, Harpreet ^a   Hütt Cabezas, Marianne ^a   Weingart, Melanie F ^a   Xu, Jingying ^c   Kuwahara, Yasumichi ^b   Erdreich Epstein, Anat ^c   Weissman, Bernard E ^b   Eberhart, Charles G ^a   Raabe, Eric H ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Atypical teratoid rhabdoid tumor; High mobility group AT hook 2; INI1; let 7; Malignant rhabdoid tumor; Pediatric brain tumor; SNF5.

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENICITY; CELL PROLIFERATION; CELL RENEWAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOID TUMOR; TERATOMA; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CARCINOGEN TESTING; CFU COUNTING; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOGENICITY TESTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; RHABDOID TUMOR; RNA, SMALL INTERFERING; TERATOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921930622     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000161     Document Type: Article

References (56)

1. Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: A highly malignant tumor of infancy and childhood frequently mistaken for medulloblastomaVA Pediatric Oncology Group study. Am J Surg Pathol 1998;22:1083-92
2. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 2009;27:385-9
3. Glauser TA, Packer RJ. Cognitive deficits in long-term survivors of childhood brain tumors. Childs Nerv Syst 1991;7:2-12
4. Biegel JA, Rorke LB, Emanuel BS. Monosomy 22 in rhabdoid or atypical teratoid tumors of the brain. N Engl J Med 1989;321:906
5. Jackson EM, Sievert AJ, Gai X, et al. Genomic analysis using high-density single-nucleotide polymorphismYbased oligonucleotide arrays and multiplex ligationYdependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res 2009;15:1923-30
6. Wei D, Goldfarb D, Song S, et al. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development. Mol Cancer Res 2014;12:1574-85
7. Hambardzumyan D, Becher OJ, Holland EC. Cancer stem cells and survival pathways. Cell Cycle 2008;7:1371-78
8. Hashizume R, Gupta N, Berger MS, et al. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro Oncol 2010;12:366-76
9. Alimova I, Birks DK, Harris PS, et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol 2013;15:149-60
10. Venneti S, Le P, Martinez D, et al. Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins. Am J Surg Pathol 2011;35:1463-72
11. Zhang K, Gao H, Wu X, et al. Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA. Clin Cancer Res 2014;20:1179-89
12. Bustin M, Reeves R. High-mobility-group chromosomal proteins: Architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 1996;54:35-100
13. Chieffi P, Battista S, Barchi M, et al. HMGA1 and HMGA2 protein expression in mouse spermatogenesis. Oncogene 2002;21:3644-50
14. Pfannkuche K, Summer H, Li O, et al. The high-mobility group protein HMGA2: A co-regulator of chromatin structure and pluripotency in stem cells? Stem Cell Rev 2009;5:224-30
15. Singh I, Mehta A, Contreras A, et al. Hmga2 is required for canonical WNT signaling during lung development. BMC Biol 2014;12:21
16. Zhou X, Benson KF, Ashar HR, et al. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-74
17. Di Cello F, Hillion J, Hristov A, et al. HMGA2 participates in transformation in human lung cancer. Molec Cancer Res 2008;6:743-50
18. Fedele M, Fusco A. HMGA and cancer. Biochim Biophys Acta 2010; 1799:48-54
19. Morishita A, Zaidi MR, Mitoro A, et al. HMGA2 is a driver of tumor metastasis. Cancer Res 2013;73:4289-99
20. Thuault S, Valcourt U, Petersen M, et al. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 2006;174:175-83
21. Watanabe S, Ueda Y, Akaboshi S, et al. HMGA2 maintains oncogenic RASYinduced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009;174:854-68
22. Efanov A, Zanesi N, Coppola V, et al. Human HMGA2 protein overexpressed in mice induces precursor TYcell lymphoblastic leukemia. Blood Cancer J 2014;4:e227
23. Kong D, Su G, Zha L, et al. Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer. Med Oncol 2014;31:130
24. Kumar MS, Armenteros-Monterroso E, East P, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature 2014;505:212-17
25. Liu B, Pang B, Hou X, et al. Expression of high-mobility group AT-hook protein 2 and its prognostic significance in malignant gliomas. Hum Pathol 2014;45:1752-58
26. Liu Q, Liu T, Zheng S, et al. HMGA2 is down-regulated by microRNA let-7 and associated with epithelial-mesenchymal transition in oesophageal squamous cell carcinomas of Kazakhs. Histopathology 2014;65:408-17
27. Fedele M, Pierantoni GM, Visone R, et al. Critical role of the HMGA2 gene in pituitary adenomas. Cell Cycle 2006;5:2045-48
28. Mahajan A, Liu Z, Gellert L, et al. HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol 2010; 23:673-81
29. Morshedi A, Ren Z, Li J, et al. Probing into the biological processes Influenced by ESC factor and oncoprotein HMGA2 using iPSCs. Stem Cell Rev 2013;9:514-22
30. Nishino J, Kim I, Chada K, et al. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf expression. Cell 2008;135:227-39
31. Sun M, Gomes S, Chen P, et al. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene 2014;33:3528-37
32. Sun M, Song CX, Huang H, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci USA 2013;110:9920-25
33. Wang X, Liu X, Li AY, et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res 2011;17:2570-80
34. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, et al. Novel cell lines established from pediatric brain tumors. J Neuro Oncol 2012;107:269-80
35. Erdreich-Epstein A, Robison N, Ren X, et al. PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas. Clin Cancer Res 2013;20:827-36
36. Xu J, Margol A, Asgharzadeh S, et al. Pediatric brain tumor cell lines. J Cell Biochem 2015;116:218-24
37. Kang MH, Smith MA, Morton CL, et al. National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011;56:239-49
38. Bax DA, Little SE, Gaspar N, et al. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One 2009;4:e5209
39. Mao XG, Hutt-Cabezas M, Orr BA, et al. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget 2013;4: 1050-64
40. Schneider CA, RasbandWS, Eliceiri KW. NIH Image to ImageJ: 25 Years of image analysis. Nat Methods 2012;9:671-75
41. Biegel JA, Pollack IF. Molecular analysis of pediatric brain tumors. Curr Oncol Rep 2004;6:445-52
42. Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol 2005;64:391-97
43. Hombach-Klonisch S, Natarajan S, Thanasupawat T, et al. Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells. Front Endocrinol 2014;5:37
44. Natarajan S, Hombach-Klonisch S, Droge P, et al. HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia 2013;15:263-80
45. Wei CH, Wei LX, Lai MY, et al. Effect of silencing of high-mobility group A2 gene on gastric cancer MKN-45 cells. World J Gastroenterol 2013;19:1239-46
46. Nunez G, Benedict MA, Hu Y, et al. Caspases: The proteases of the apoptotic pathway. Oncogene 1998;17:3237-45
47. Boulares AH, Yakovlev AG, Ivanova V, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999;274:22932-40
48. Winter N, Nimzyk R, Bosche C, et al. Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2. PloS One 2011;6:e18837
49. Zha L, Wang Z, Tang W, et al. Genome-wide analysis of HMGA2 transcription factor binding sites by ChIP on chip in gastric carcinoma cells. Mol Cell Biochem 2012;364:243-51
50. Li O, Li J, Droge P. DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells. FEBS Lett 2007;581:3533-37
51. Reeves R. Molecular biology of HMGA proteins: Hubs of nuclear function. Gene 2001;277:63-81
52. Geierstanger BH, Volkman BF, Kremer W, et al. Short peptide fragments derived from HMG-I/Y proteins bind specifically to the minor groove of DNA. Biochemistry 1994;33:5347-55
53. Reeves R, Nissen MS. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 1990;265:8573-82
54. Wegner M, Grummt F. Netropsin, distamycin and berenil interact differentially with a high-affinity binding site for the high mobility group protein HMG-I. Biochem Biophys Res Com 1990;166:1110-17
55. Wong SS, Sturm RA, Michel J, et al. Transcriptional regulation of differentiation, selective toxicity and ATGCAAAT binding of bisbenzimidazole derivatives in human melanoma cells. Biochem Pharmacol 1994;47:827-37
56. Lau KM, Chan QK, Pang JC, et al. Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma. Acta Neuropathol 2012;123:553-71